JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Talphera Inc.

Abrir

1.22 -3.94

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.22

Máximo

1.26

Indicadores-chave

By Trading Economics

Funcionários

13

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+130.77% upside

Dividendos

By Dow Jones

Próximos Ganhos

12 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

37M

45M

Abertura anterior

5.16

Fecho anterior

1.22

Talphera Inc. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de out. de 2025, 23:50 UTC

Ações em Alta

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 de out. de 2025, 23:25 UTC

Ganhos

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 de out. de 2025, 23:18 UTC

Ganhos

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 de out. de 2025, 22:20 UTC

Ganhos

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 de out. de 2025, 22:13 UTC

Ganhos

Wal-Mart de Mexico Net Profit Falls in 3Q

28 de out. de 2025, 21:38 UTC

Ganhos

Correction to Visa Sales Jump Article

28 de out. de 2025, 21:17 UTC

Ganhos

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 de out. de 2025, 21:07 UTC

Ganhos

Visa Sales Jump as Consumers Keep Spending -- Update

28 de out. de 2025, 21:02 UTC

Ganhos

Mondelez Tempers Outlook as Costs Rise

28 de out. de 2025, 23:51 UTC

Conversa de Mercado

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 de out. de 2025, 23:42 UTC

Conversa de Mercado

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 de out. de 2025, 23:02 UTC

Ganhos

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 de out. de 2025, 23:01 UTC

Ganhos

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 de out. de 2025, 22:46 UTC

Ganhos

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 de out. de 2025, 22:45 UTC

Ganhos

SK Hynix 3Q Net KRW12.6T >000660.SE

28 de out. de 2025, 22:44 UTC

Ganhos

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 de out. de 2025, 22:43 UTC

Ganhos

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 de out. de 2025, 22:42 UTC

Ganhos

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 de out. de 2025, 22:40 UTC

Ganhos

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 de out. de 2025, 22:40 UTC

Ganhos

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 de out. de 2025, 22:20 UTC

Ganhos

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 de out. de 2025, 22:02 UTC

Ganhos

Review & Preview: Earnings Extravaganza -- Barrons.com

28 de out. de 2025, 21:42 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

28 de out. de 2025, 21:42 UTC

Conversa de Mercado
Ganhos

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 de out. de 2025, 21:20 UTC

Ganhos

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 de out. de 2025, 21:19 UTC

Ganhos

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 de out. de 2025, 21:18 UTC

Ganhos

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparação entre Pares

Variação de preço

Talphera Inc. Previsão

Preço-alvo

By TipRanks

130.77% parte superior

Previsão para 12 meses

Média 3 USD  130.77%

Máximo 3 USD

Mínimo 3 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Talphera Inc. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

1

Comprar

0

Manter

0

Vender

Informação Financeira

$

Sobre Talphera Inc.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
help-icon Live chat